These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Hypertrophic cardiomyopathy with restrictive pathophysiology: is there a role for cardiopulmonary exercise testing?]. Correale M; Passero T; Totaro A; Di Biase M G Ital Cardiol (Rome); 2012 Dec; 13(12):861; author's reply p.861. PubMed ID: 23196690 [No Abstract] [Full Text] [Related]
7. Hypertrophic cardiomyopathy: therapeutic approaches. Thomas B Heart Dis; 1999; 1(2):91-7. PubMed ID: 11720609 [TBL] [Abstract][Full Text] [Related]
8. Management of symptomatic hypertrophic cardiomyopathy: pills, alcohol, or the scalpel? Gersh BJ; Nishimura RA Rev Esp Cardiol (Engl Ed); 2014 May; 67(5):341-4. PubMed ID: 24774724 [No Abstract] [Full Text] [Related]
10. New perspectives in the pharmacological treatment of hypertrophic cardiomyopathy. Maltês S; Lopes LR Rev Port Cardiol (Engl Ed); 2020 Feb; 39(2):99-109. PubMed ID: 32245685 [TBL] [Abstract][Full Text] [Related]
12. September 2016 at a glance: pregnancy, hypertrophic cardiomyopathy, epidemiology, medical treatment. Metra M Eur J Heart Fail; 2016 Sep; 18(9):1091-2. PubMed ID: 27594173 [No Abstract] [Full Text] [Related]
13. Dealing with a special group: hypertrophic cardiomyopathy. The role of electrophysiology and pacing in hypertrophic cardiomyopathy. de Sousa J Rev Port Cardiol; 1999 Sep; 18 Suppl 5():V51-3. PubMed ID: 10582459 [No Abstract] [Full Text] [Related]
14. Hypertrophic cardiomyopathy. Pathophysiology, diagnosis, and treatment. Popjes ED; St John Sutton M Geriatrics; 2003 Mar; 58(3):41-6; quiz 47. PubMed ID: 12650117 [TBL] [Abstract][Full Text] [Related]
15. [On the work by S. Reith and H. G. Klues "Therapy and risk-stratification in hypertrophic cardiomyopathy", Z Kardiol 92: 283-293 (2003)]. Schwab J; Bareiter T; Bär I; Gottwik M Z Kardiol; 2003 Sep; 92(9):763. PubMed ID: 14508595 [No Abstract] [Full Text] [Related]
16. [The electrocardiogram in apical hypertrophic myocardiopathy. A case report with unique manifestations]. Penas Lado M; Mosquera Pérez I; Bouzas Zubeldía B; Vázquez Rodríguez JM; Castro Beiras A Rev Esp Cardiol; 1999 Dec; 52(12):1148-50. PubMed ID: 10659661 [TBL] [Abstract][Full Text] [Related]
17. Sixty Years of Hemodynamic Pharmacology in Obstructive Hypertrophic Cardiomyopathy. Ommen SR N Engl J Med; 2024 May; 390(20):1914-1915. PubMed ID: 38739083 [No Abstract] [Full Text] [Related]
18. Dealing with a special group: hypertrophic cardiomyopathy. Etiology and prevalence: what is known today. Komajda M Rev Port Cardiol; 1999 Sep; 18 Suppl 5():V41-4. PubMed ID: 10582456 [No Abstract] [Full Text] [Related]
19. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study. Bauersachs J; Störk S; Kung M; Waller C; Fidler F; Hoyer C; Frantz S; Weidemann F; Ertl G; Angermann CE Eur J Clin Invest; 2007 Nov; 37(11):852-9. PubMed ID: 17973781 [TBL] [Abstract][Full Text] [Related]
20. Sudden cardiac death due to hypertrophic cardiomyopathy can be reduced by pre-participation cardiovascular screening in young athletes. Panhuyzen-Goedkoop NM; Verheugt FW Eur Heart J; 2006 Sep; 27(18):2152-3. PubMed ID: 16877480 [No Abstract] [Full Text] [Related] [Next] [New Search]